From: Clinical management of gastric cancer: results of a multicentre survey
Neoadjuvant practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists | p | |||
---|---|---|---|---|---|---|---|---|
 |  | N | % | N | % | N | % |  |
adenocarcinoma cT4N0M0 | gastrectomy or preoperative chemotherapy | Â | Â | Â | Â | Â | Â | 0.612 |
gastrectomy | Â | 40 | 39.60 | 75 | 46.58 | 27 | 28.13 | Â |
preoperative chemotherapy | Â | 48 | 47.52 | 72 | 44.72 | 41 | 42.71 | Â |
preoperative radiotherapy | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
preoperative chemoradiation | Â | 13 | 12.87 | 14 | 8.70 | 28 | 29.17 | Â |
adenocarcinoma cT2N2M0 | gastrectomy or preoperative chemotherapy | Â | Â | Â | Â | Â | Â | 0.040 |
gastrectomy | Â | 70 | 69.31 | 77 | 47.83 | 30 | 31.25 | Â |
preoperative chemotherapy | Â | 18 | 17.82 | 73 | 45.34 | 38 | 39.58 | Â |
preoperative radiotherapy | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
preoperative chemoradiation | Â | 13 | 12.87 | 11 | 6.83 | 28 | 29.17 | Â |
regimen usually used in neoadjuvant setting | ECF(EPI+DDP+5FU) | Â | Â | Â | Â | Â | Â | 0.634 |
CF(DDP+5FU) | Â | 21 | 20.79 | 29 | 18.01 | 15 | 15.63 | Â |
ECF(EPI+DDP+5FU) | Â | 15 | 14.85 | 35 | 21.74 | 14 | 14.58 | Â |
fluoropyrimidine(5Fu or Capecitabine) | Â | 24 | 23.76 | 7 | 4.35 | 7 | 7.30 | Â |
oxaliplatin based regimen | Â | 23 | 22.77 | 63 | 39.13 | 35 | 36.46 | Â |
irinotecan based regimen | Â | 12 | 11.88 | 5 | 3.11 | 9 | 9.38 | Â |
paclitaxel or docetaxel based regimen | Â | 6 | 5.94 | 22 | 13.66 | 16 | 16.67 | Â |
combination of above or other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
how long neoadjuvant chemotherapy last | 3 cycles, about 2 months | Â | Â | Â | Â | Â | Â | 0.213 |
< 1 m | Â | 21 | 20.79 | 19 | 11.80 | 8 | 8.33 | Â |
1-3 m | Â | 76 | 75.25 | 127 | 78.88 | 79 | 82.29 | Â |
> 3 m | Â | 4 | 3.96 | 15 | 9.32 | 9 | 9.38 | Â |